{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-158211","form_type":"8-K","ticker":"NAMS","cik":"0001936258","company_name":"NewAmsterdam Pharma Co N.V.","filed_at":"2025-07-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.642201+00:00","generated_at":"2026-05-18T06:59:34.892239+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"NewAmsterdam Pharma amends CSO Kastelein's employment agreement with enhanced severance","bullets":["Amended agreement effective July 1, 2025; replaces November 2022 pact.","Termination without cause entitles Kastelein to 12 months base salary, earned bonus, and prorated annual bonus.","Change-in-control trigger: same severance plus acceleration of all time-based stock options and equity awards.","Exercise period for certain vested options extended upon qualifying termination.","Kastelein remains Chief Scientific Officer and a director; no departure announced."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-158211","json":"https://secwatch.observer/filing/0001193125-25-158211.json","markdown":"https://secwatch.observer/filing/0001193125-25-158211.md","text":"https://secwatch.observer/filing/0001193125-25-158211.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1936258/000119312525158211/0001193125-25-158211-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1936258/000119312525158211/d915297d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T06:59:34.892239+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}